by Aline Fieck | May 6, 2025 | Featured, News
PARIS, FRANCE, May 6, 2025 – We are thrilled to share that Qynapse’s collaborative study with Amsterdam UMC has been published in Alzheimer’s Research & Therapy: “Clinical phenotypes of Alzheimer’s disease: investigating atrophy patterns and their pathological...
by Aline Fieck | Apr 5, 2025 | Featured, News
PARIS, FRANCE, April 5, 2025 –Dr. Luca Villa, Senior Clinical Scientist, presented our work focused on using QyScore® and QyPredict® to differentiate patients with progressive supranuclear palsy from patients with Parkinson’s disease. The presentation, titled...
by Aline Fieck | Feb 12, 2025 | Featured, News
PARIS, FRANCE, February 12, 2024 – Qynapse had the pleasure of participating in “Challenges of AI in Healthcare”, an event organized by PariSanté Campus and French Healthcare Association as part of the AI Action Summit in Paris. This gathering brought...
by Aline Fieck | Jan 15, 2025 | Featured, News
PARIS, FRANCE, January 15 28, 2025 – Qynapse congratulates Anavex Life Sciences on the peer-reviewed publication of the ANAVEX®2-73-AD-004 Phase IIb/III clinical trial in The Journal of Prevention of Alzheimer’s Disease. This 48-week randomized, placebo-controlled...
by Alexandre Beaurain | May 10, 2024 | Featured, News
PARIS, FRANCE, May 8, 2024 – Our CEO, Olivier Courrèges, will be presenting at the HITLAB Summit in New York City this week! Olivier’s presentation “AI Opening a New Era of Prediction and Monitoring for CNS Diseases.” is scheduled for May 8th at...
by Administrators Qynapse | Feb 28, 2024 | Featured, News
PARIS, FRANCE, February 28, 2024 – In the exciting context of effective new Alzheimer’s disease treatments, Qynapse are pleased to present our work at the upcoming AD/PD 2024 addressing the need for accurate standardized quantification of amyloid PET with...
